Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


Greg Collier ChemGenex CEO Awarded at AusBiotech

28 October 2009


ChemGenex CEO Dr Greg Collier was today recognised for his outstanding contribution to the Australian biotech sector, receiving the AusBiotech 2009 Chairman’s Excellence Award for outstanding contribution by an individual within a company.

Dr Collier has played a significant role internationally and domestically in promoting Australia’s leadership in biotechnology development and commercialisation. Under Dr Collier’s leadership ChemGenex has emerged as an Australian success story, being the first Australian company to submit a New Drug Application (NDA) to the US Food and Drug Administration for a cancer medicine.

ChemGenex has submitted its NDA for Omapro™ (omacetaxine mepesuccinate), for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with the drug imatinib and who have developed the T315I mutation. Patients with this mutation do not respond to existing therapies, and in clinical trials Omapro has been shown to be effective in 85% of patients with chronic phase CML.

ChemGenex also recently discovered in preclinical testing that Omapro kills human leukemic stem cells - a significant development with research showing stem cells appear to fuel the growth of several kinds of cancers including leukemia and are resistant to standard cancer therapy.

With stem cell therapies being hailed by many as the silver bullet in cancer treatment, this discovery is an interesting development for the Company and expands potential new and wide ranging avenues for the use of Omapro.

Dr Collier has more than 20 years’ experience spanning commercial, operational, clinical and scientific aspects of pharmaceutical research and development. He has been CEO of ChemGenex for seven years.

In presenting the awards, AusBiotech Chairman Dr Deborah Rathjen said: “Dr Collier has made a sustained and significant contribution to the Australian biotechnology industry not only through his achievements at ChemGenex but in his general pursuits in the discovery and commercialisation of Australian research in the important area of cancer therapies.”

AusBiotech is the national body for the biotechnology and life sciences industry, hosting AusBiotech 2009 – the premier Australasian biotechnology conference from 27 – 30 October in Melbourne.

About AusBiotech

AusBiotech is Australia’s voice on biotechnology, and represents more than 3,000 members, encompassing medicines, medical diagnostics and devices, agriculture, alternative fuels and climate change.

For additional event information visit the conference website at:


© Scoop Media

Business Headlines | Sci-Tech Headlines


Commerce Commission: Latest Broadband Report Confirms Improved Performance Of Premium Fibre Plans

The latest report from the Commerce Commission’s Measuring Broadband New Zealand programme shows that the performance of Fibre Max plans has improved substantially. This follows a collaboration between the Commission, its independent testing partner, ... More>>

Air New Zealand: Capital Raise Deferred

Air New Zealand has decided to defer its planned capital raise to later in 2021 allowing more time to assess the impacts of recent developments on the airline’s path to recovery. 'We’ve seen some clearing of COVID-19 clouds recently, with ... More>>

Commerce Commission: Cartel Conduct Now Punishable By Up To 7 Years’ Jail Time

Cartel conduct can now be punished with a term of imprisonment of up to 7 years, after the Commerce (Criminalisation of Cartels) Amendment Act 2019 came into effect today. Cartel conduct includes price fixing, market allocation and bid rigging (see ... More>>

Stats NZ: Auckland Population May Hit 2 Million In Early 2030s

Auckland’s population may rise from about 1.7 million currently to 2 million by early next decade, Stats NZ said today. “Auckland will likely have the highest average annual growth of New Zealand’s 16 regions over the next 30 years, from ... More>>

Stats NZ: March Card Spending Rebounds Despite COVID

There was a lift in retail card spending in March following a fall in the lockdown-disrupted February month, Stats NZ said today. Seasonally adjusted retail card spending rose by $53 million (0.9 percent), compared with February 2021. Visit our website to read ... More>>

PwC: Outcome Of Review Into Air New Zealand Gas Turbines Business

Air New Zealand has received the report into its Gas Turbines business from independent external advisers PwC. Air New Zealand Chairman Dame Therese Walsh says the report identified a range of effective controls in the Gas Turbines revenue contracting ... More>>

LPG Association: Renewable LPG Achieves Emissions Budgets With No Need To Ban New LPG Connections

Renewable LPG can supply New Zealand’s LPG needs and achieve the emissions reductions proposed by the Climate Commission without the need to ban new connections, a new study shows. The investigation, by leading consultancy Worley, was prepared for the ... More>>